Liquid Biopsy Market Share

ID: MRFR/HC/0239-CR

171 Pages

Kinjoll Dey

February 2023

Liquid Biopsy Market Research Report By Application (Cancer Diagnosis, Treatment Monitoring, Recurrence Monitoring, Clinical Trials, Research Applications), By Sample Type (Blood, Urine, Saliva, Pleural Fluid, Cerebrospinal Fluid), By Technology (Next Generation Sequencing, Digital PCR, Microfluidics, Exosome Isolation, Circulating Tumor Cells), By End Use (Hospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast ... read more

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Share

Liquid Biopsy Market Share Analysis

Liquid biopsy plays a pivotal role in the identification of specific genomic alterations, offering valuable insights for guiding treatment decisions. This innovative approach allows for real-time monitoring of tumor burden, enabling precise evaluation of recurrence risks in diseases like cancer. The qualitative and quantitative information obtained through liquid biopsy aids healthcare professionals in comprehending any potential resistance mechanisms to drugs. This detailed knowledge assists in determining the most effective course of action for drug regimens, facilitating the creation of customized and personalized treatment plans based on the genetic profiling obtained through liquid biopsy. The global cancer burden is expected to escalate significantly, with a predicted 50% increase, reaching 15 million new cases by 2020, according to the World Cancer Report by the World Health Organization (WHO). In 2012 alone, there were 14 million new cases and 8.2 million cancer-related deaths worldwide, a number projected to reach 22 million within the next two decades. Africa, Asia, and Central and South America collectively account for two-thirds of cases and three-fourths of deaths. Specific cancers projected to experience growth include breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, bladder cancer, melanoma of the skin, non-Hodgkin lymphoma, thyroid cancer, kidney and renal pelvis cancer, leukemia, endometrial cancer, and pancreatic cancer. Considering the rising prevalence of these cancers, liquid biopsy emerges as an effective tool with substantial growth potential.

Cardiovascular diseases (CVDs) currently lead in global mortality rates, with an estimated 17.5 million people succumbing to CVDs in 2012, representing one-third of all global deaths. The effectiveness of liquid biopsy in treating these prevalent diseases underscores its growth potential.

The WHO underscores that tobacco use is the foremost avoidable risk factor for cancer mortality globally, claiming around 6 million lives annually from cancer and other related diseases. Additional environmental factors, such as certain infections (hepatitis, human papillomavirus), exposure to ionizing radiation, and pollutants, further contribute to the spread of diseases like cancer and cardiovascular diseases, creating a conducive environment for the application of liquid biopsy.

Comparing liquid biopsy to traditional tissue biopsies reveals significant advantages. Traditional tissue biopsies, costing between US$15,000 to US$60,000 with a failure rate of approximately 25%, are outperformed by liquid biopsy in terms of sensitivity, detection rates, and lower failure rates. The Polymerase Chain Reaction (PCR) technology employed in liquid biopsies represents a substantial advancement over the Sanger sequencing utilized in tissue biopsies, particularly for detecting low-frequency variants. Moreover, liquid biopsies have substantially reduced the costs associated with traditional tissue biopsies. For instance, Pathway Genomics introduced its first liquid biopsy, Cancer Intercept, priced at a mere $299, while Guardant360 is available for $5,800, presenting a cost-effective alternative to traditional biopsy methods.

In summary, liquid biopsy's ability to offer real-time monitoring, personalized treatment plans, and cost-effectiveness positions it as a critical player in the diagnosis and treatment of prevalent diseases like cancer and cardiovascular diseases. As these health challenges continue to rise globally, liquid biopsy stands out as a valuable and increasingly accessible tool in the medical field.

Market Highlights

Author

Kinjoll Dey

Research Analyst Level I

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch

FAQs

What is the projected growth of the Liquid Biopsy market?

The Liquid Biopsy market is the expected increase in total market value of 27.34 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Liquid Biopsy market?

Liquid Biopsy market size was valued at approximately 9.1 billion USD in 2024. This figure will reach 27.34 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Liquid Biopsy market?

Liquid Biopsy market is expected to grow at a CAGR of 10.52% between 2025 and 2035.

How much will the Liquid Biopsy market be worth by 2035?

Liquid Biopsy market is expected to be worth of 27.34 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Liquid Biopsy market perform over the next 10 years?

Over the next 10 years the Liquid Biopsy market is expected to shift from usd billion 9.1 to 27.34 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

Which region is expected to dominate the Global Liquid Biopsy Market in 2024?

North America is expected to dominate the Global Liquid Biopsy Market with a value of 2.5 USD Billion in 2024.

What will be the market size of the Global Liquid Biopsy Market in Europe by 2035?

The market size for the Global Liquid Biopsy Market in Europe is projected to reach 3.8 USD Billion by 2035.

What is the forecasted market size for Cancer Diagnosis within the Global Liquid Biopsy Market in 2035?

The market size for Cancer Diagnosis is expected to reach 5.9 USD Billion in 2035.

Who are some of the major players in the Global Liquid Biopsy Market?

Major players in the Global Liquid Biopsy Market include GRAIL, Natera, Foundation Medicine, and Thermo Fisher Scientific.

What is the anticipated market size for Treatment Monitoring in 2024?

The anticipated market size for Treatment Monitoring in 2024 is 1.3 USD Billion.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per MRFR analysis, the Liquid Biopsy Market Size was estimated at 9.1 USD Billion in 2024. The Liquid Biopsy industry is projected to grow from 10.06 USD Billion in 2025 to 27.34 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 10.52 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Liquid Biopsy Market is poised for substantial growth driven by technological advancements and increasing demand for personalized medicine.

North America remains the largest market for liquid biopsy, driven by robust healthcare infrastructure and high cancer incidence rates.
Asia-Pacific is emerging as the fastest-growing region, fueled by increasing investments in healthcare and rising awareness of early cancer detection.
Oncology continues to dominate the market as the largest segment, while prenatal testing is rapidly gaining traction as the fastest-growing segment.
Key market drivers include the rising incidence of cancer and advancements in technology, which are propelling the demand for minimally invasive procedures.

Market Size & Forecast

2024 Market Size	9.1 (USD Billion)
2035 Market Size	27.34 (USD Billion)
CAGR (2025 - 2035)	10.52%
Largest Regional Market Share in 2024	North America

Major Players

Guardant Health (US), Exact Sciences (US), GRAIL (US), Freenome (US), Biocept (US), Sysmex Corporation (JP), Roche Diagnostics (CH), Qiagen (DE), Thermo Fisher Scientific (US)

Market Trends

The Liquid Biopsy Market is currently experiencing a transformative phase, characterized by advancements in technology and increasing acceptance among healthcare professionals. This innovative approach to cancer diagnostics and monitoring offers a non-invasive alternative to traditional tissue biopsies, which often involve surgical procedures. The growing prevalence of cancer globally has heightened the demand for effective diagnostic tools, and liquid biopsies appear to provide a promising solution. Furthermore, the integration of artificial intelligence and machine learning into liquid biopsy analysis is likely to enhance accuracy and efficiency, potentially revolutionizing patient care. In addition to technological advancements, regulatory support is becoming more pronounced, as governing bodies recognize the potential of liquid biopsies in clinical settings. This support may facilitate faster approvals and encourage research and development in this field. Moreover, the increasing focus on personalized medicine suggests that liquid biopsies could play a crucial role in tailoring treatment plans to individual patients. As the Liquid Biopsy Market continues to evolve, it seems poised for substantial growth, driven by innovation, regulatory backing, and a shift towards more patient-centric healthcare solutions.

Technological Advancements

Recent innovations in liquid biopsy technologies are enhancing the sensitivity and specificity of cancer detection. Techniques such as next-generation sequencing and digital droplet PCR are becoming more prevalent, allowing for the identification of genetic mutations and circulating tumor DNA with greater precision. This trend indicates a shift towards more reliable diagnostic methods that could improve patient outcomes.

Regulatory Support

The increasing recognition of liquid biopsies by regulatory agencies is fostering a more favorable environment for market growth. As guidelines evolve to incorporate these non-invasive tests, manufacturers may find it easier to navigate the approval process. This regulatory support could lead to a wider adoption of liquid biopsy technologies in clinical practice.

Personalized Medicine Focus

The emphasis on personalized medicine is driving interest in liquid biopsies, as these tests can provide insights into individual tumor characteristics. By enabling tailored treatment strategies, liquid biopsies may enhance therapeutic efficacy and minimize adverse effects. This trend suggests a growing alignment between liquid biopsy applications and the broader goals of precision oncology.

Liquid Biopsy Market Market Drivers

Rising Incidence of Cancer

The increasing prevalence of cancer globally serves as a primary driver for the Global Liquid Biopsy Market Industry. As cancer cases rise, the demand for early detection and monitoring solutions intensifies. Liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, allowing for the analysis of circulating tumor DNA. For instance, the World Health Organization indicates that cancer cases are expected to reach 30 million by 2040. This growing patient population is likely to propel the market, with projections estimating the Global Liquid Biopsy Market to reach 8.9 USD Billion in 2024 and potentially 22.9 USD Billion by 2035.

Market Segment Insights

By Application: Oncology (Largest) vs. Prenatal Testing (Fastest-Growing)

In the Liquid Biopsy Market, Oncology holds the largest share, comprising a significant percentage of the total revenues. It dominates due to the increasing prevalence of cancer and the growing recognition of liquid biopsies as a less invasive method for early detection and monitoring. Other segments, such as Non-Oncology and Infectious Disease, also contribute, albeit on a smaller scale, indicating a diversified application landscape within the market. As awareness and technology evolve, these segments are expected to capture more attention and investment in the coming years.

Oncology: Dominant vs. Prenatal Testing: Emerging

Oncology remains the dominant application segment within the Liquid Biopsy Market, attributed to the urgent need for cancer detection and monitoring solutions. The non-invasive nature of liquid biopsies allows for frequent testing and real-time tracking of tumor dynamics, making them invaluable in oncological care. On the other hand, Prenatal Testing, while currently smaller in scale, is rapidly emerging due to advancements in genetic testing technologies. This segment benefits from increasing demand for safe and effective prenatal screenings, which can impact maternal and fetal health positively. As research progresses, both segments are likely to expand, driven by technological innovations and evolving clinical applications.

By Sample Type: Blood (Largest) vs. Urine (Fastest-Growing)

Among the sample types analyzed in the liquid biopsy market, blood accounts for the largest share due to its widespread acceptance and utility in clinical settings for a variety of cancers. It serves as the primary medium for detecting circulating tumor DNA, making it an essential tool for non-invasive diagnostics. Following blood, urine is emerging rapidly, fueled by its minimally invasive collection methods and increasing adoption in early cancer detection systems.

Blood (Dominant) vs. Urine (Emerging)

The blood sample type remains dominant in the liquid biopsy market as it facilitates comprehensive analysis of tumor dynamics through circulating tumor cells and cell-free DNA. Its established role in oncology and compatibility with various technologies has solidified its position. On the other hand, urine is an emerging sample type, gaining traction due to innovations in detection techniques. Its ease of collection makes it attractive for patient compliance and large-scale screenings, particularly for bladder cancer and other urological malignancies. As research progresses, urine-based liquid biopsies are expected to carve out a significant niche alongside blood-based methods.

By Technology: Next Generation Sequencing (Largest) vs. Digital PCR (Fastest-Growing)

In the Liquid Biopsy Market, the segmentation by technology reveals that Next Generation Sequencing (NGS) holds the largest market share, driven by its advanced capabilities in genomic analysis and high-throughput screening. Digital PCR follows closely, emerging as a significant contender and catering to precise quantification of DNA, making it vital for monitoring treatment responses effectively. Meanwhile, other technologies such as Microfluidics, Mass Spectrometry, and Circulating Tumor Cell Technology also play essential roles but command smaller portions of the overall market.

Next Generation Sequencing (Dominant) vs. Digital PCR (Emerging)

Next Generation Sequencing (NGS) leads the Liquid Biopsy Market due to its ability to analyze vast genomic information rapidly, enabling early cancer detection and personalized medicine. Its technological advancements have established it as a preferred choice for researchers and clinicians alike. In contrast, Digital PCR is gaining momentum as an emerging technology favored for its sensitivity and specificity in quantifying rare mutations, which is crucial in treatment monitoring and progression assessment. As healthcare emphasizes precision medicine, the traction of Digital PCR is anticipated to grow significantly due to its superior performance in detecting low-abundance targets.

By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the Liquid Biopsy Market, hospitals hold the largest share among end users, driven by their comprehensive capabilities in patient care and advanced diagnostic technologies. They serve as central hubs for conducting liquid biopsy procedures, resulting in the highest volume of tests performed. In contrast, diagnostic laboratories are witnessing rapid growth, spurred by the increasing demand for timely and accurate cancer diagnostics, leading to a significant uptick in service offerings and technological advancements in laboratory settings.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals play a dominant role in the Liquid Biopsy Market due to their integrated healthcare services and ability to provide immediate patient care, which enhances the adoption of liquid biopsy tests. Their established infrastructure for complex diagnostics supports a thriving environment for innovative cancer detection solutions. On the other hand, diagnostic laboratories are emerging as crucial players, benefiting from their specialized focus on testing and analysis. This sector is rapidly evolving to incorporate advanced technologies that cater to the growing need for precise and efficient diagnostic services. As more laboratories invest in the capabilities to perform liquid biopsies, they position themselves as vital contributors to the market's expansion.

Get more detailed insights about Liquid Biopsy Market Research Report - Global Forecast to 2035

Regional Insights

North America : Market Leader in Innovation

North America continues to lead the liquid biopsy market, holding a significant share of 4.55 billion in 2024. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of cancer, and rising demand for non-invasive diagnostic methods. Regulatory support from agencies like the FDA has further catalyzed innovation, allowing for rapid adoption of new technologies and therapies. The United States is the primary contributor to this market, with key players such as Guardant Health, Exact Sciences, and GRAIL leading the charge. The competitive landscape is characterized by continuous innovation and strategic partnerships, enhancing the availability of liquid biopsy solutions. As the market evolves, the focus on personalized medicine and early detection is expected to drive further growth in this region.

Europe : Emerging Market with Potential

Europe's liquid biopsy market is projected to reach 2.73 billion by 2025, driven by increasing cancer incidences and advancements in diagnostic technologies. The region benefits from strong regulatory frameworks that encourage innovation and ensure patient safety. Initiatives by the European Medicines Agency (EMA) are pivotal in promoting the integration of liquid biopsy into clinical practice, enhancing its acceptance among healthcare providers. Leading countries such as Germany, France, and the UK are at the forefront of this market, with a growing number of startups and established companies like Roche Diagnostics and Qiagen making significant contributions. The competitive landscape is marked by collaborations between academic institutions and industry players, fostering research and development in liquid biopsy technologies. This synergy is expected to propel market growth and improve patient outcomes.

Asia-Pacific : Rapidly Growing Market

The Asia-Pacific liquid biopsy market, valued at 1.82 billion, is experiencing rapid growth due to increasing healthcare investments and rising awareness of cancer diagnostics. Countries like China and Japan are leading this expansion, supported by government initiatives aimed at improving cancer care. The region's diverse population and high cancer prevalence are significant drivers for the adoption of liquid biopsy technologies, which offer non-invasive testing options. The competitive landscape is evolving, with both local and international players, including Sysmex Corporation, entering the market. Collaborations and partnerships are becoming common as companies seek to enhance their product offerings and expand their market reach. As regulatory frameworks improve, the potential for liquid biopsy solutions in this region is expected to grow significantly, addressing the urgent need for effective cancer diagnostics.

Middle East and Africa : Emerging Market Opportunities

The Middle East and Africa (MEA) liquid biopsy market, currently valued at 0.1 billion, is in its nascent stages but shows promising growth potential. Factors such as increasing cancer rates and a shift towards personalized medicine are driving interest in liquid biopsy technologies. Governments in the region are beginning to recognize the importance of advanced diagnostic tools, which may lead to supportive regulatory frameworks in the future. Countries like South Africa and the UAE are emerging as key players in this market, with a growing number of healthcare facilities adopting innovative diagnostic solutions. The competitive landscape is still developing, with opportunities for both local and international companies to establish a presence. As awareness and infrastructure improve, the liquid biopsy market in MEA is expected to expand, addressing the region's healthcare challenges.

Key Players and Competitive Insights

The Liquid Biopsy Market is currently characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for non-invasive diagnostic solutions. Key players such as Guardant Health (US), Exact Sciences (US), and Roche Diagnostics (CH) are at the forefront, each adopting distinct strategies to enhance their market presence. Guardant Health (US) focuses on innovation in genomic profiling, aiming to provide comprehensive insights into cancer treatment. Meanwhile, Exact Sciences (US) emphasizes partnerships with healthcare providers to expand its testing capabilities, thereby enhancing patient access to liquid biopsy solutions. Roche Diagnostics (CH) leverages its extensive research and development resources to integrate liquid biopsy technologies into its existing diagnostic portfolio, indicating a strategic focus on holistic healthcare solutions.

The business tactics employed by these companies reflect a concerted effort to optimize operations and enhance market penetration. The Liquid Biopsy Market appears moderately fragmented, with a mix of established players and emerging startups. This structure allows for diverse approaches to market entry and growth, with key players influencing the competitive dynamics through strategic collaborations and localized manufacturing initiatives. The collective influence of these companies shapes a landscape where innovation and operational efficiency are paramount.

In November 2025, Guardant Health (US) announced a collaboration with a leading pharmaceutical company to develop companion diagnostics for targeted therapies. This strategic move is likely to enhance the company's position in precision medicine, aligning its liquid biopsy solutions with the evolving needs of oncologists and patients. Such partnerships may facilitate faster regulatory approvals and broaden the application of their technologies in clinical settings.

In October 2025, Exact Sciences (US) launched a new liquid biopsy test aimed at early cancer detection, which is expected to significantly improve patient outcomes. This initiative underscores the company's commitment to innovation and its strategic focus on expanding its product offerings. By enhancing its testing capabilities, Exact Sciences (US) positions itself as a leader in the early detection segment, potentially capturing a larger share of the market.

In September 2025, Roche Diagnostics (CH) unveiled a new platform that integrates artificial intelligence (AI) with its liquid biopsy testing processes. This development not only streamlines operations but also enhances the accuracy of test results, reflecting a broader trend towards digitalization in the healthcare sector. The integration of AI is likely to provide Roche with a competitive edge, as it aligns with the increasing demand for precision and efficiency in diagnostics.

As of December 2025, the Liquid Biopsy Market is witnessing trends that emphasize digitalization, sustainability, and AI integration. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and enhancing product offerings. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident. Moving forward, competitive differentiation will likely hinge on the ability to innovate and adapt to the rapidly evolving healthcare environment, with companies that prioritize technology and patient-centric solutions poised to lead the market.

Key Companies in the Liquid Biopsy Market market include

Industry Developments

Recent developments in the Global Liquid Biopsy Market have seen significant advancements, with liquid biopsy companies like GRAIL and Exact Sciences pushing innovative technologies and applications. Major players are expanding their portfolios and improving diagnostic capabilities for early cancer detection.

In September 2023, Natera announced the successful launch of a new assay aimed at enhancing non-invasive prenatal testing, showcasing a potential overlap in liquid biopsy technology. Meanwhile, in August 2023, a collaboration between Foundation Medicine and Roche focused on integrating liquid biopsies into their existing genomic profiling services, emphasizing the increased relevance of these tests in personalized medicine.

On the mergers and acquisitions front, Thermo Fisher Scientific acquired Brammer Bio in December 2022, with implications for its liquid biopsy capabilities. Growth in market valuation continues to accelerate, attributed to rising collaborations across liquid biopsy companies, including Guardant Health and Illumina, as they enhance product offerings and expand their reach in the oncology segment.

Significant happenings over the last few years include the establishment of regulatory frameworks facilitating liquid biopsy integration into clinical practices, further confirming their positioning in oncology diagnostics on a global scale.

Future Outlook

Liquid Biopsy Market Future Outlook

The Liquid Biopsy Market is projected to grow at a 10.52% CAGR from 2024 to 2035, driven by technological advancements, increasing cancer prevalence, and demand for non-invasive diagnostics.

New opportunities lie in:

Development of advanced liquid biopsy platforms for early cancer detection
Partnerships with healthcare providers for integrated diagnostic solutions
Expansion into emerging markets with tailored liquid biopsy services

By 2035, the Liquid Biopsy Market is expected to be a pivotal component of cancer diagnostics.

Market Segmentation

Liquid Biopsy Market End User Outlook

Hospitals
Diagnostic Laboratories
Research Institutions
Pharmaceutical Companies
Academic Institutions

Liquid Biopsy Market Technology Outlook

Next Generation Sequencing
Digital PCR
Microfluidics
Mass Spectrometry
Circulating Tumor Cell Technology

Liquid Biopsy Market Application Outlook

Oncology
Non-Oncology
Prenatal Testing
Transplantation
Infectious Disease

Liquid Biopsy Market Sample Type Outlook

Blood
Urine
Saliva
Tissue
Bone Marrow

Report Scope

MARKET SIZE 2024	9.1(USD Billion)
MARKET SIZE 2025	10.06(USD Billion)
MARKET SIZE 2035	27.34(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	10.52% (2024 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Guardant Health (US), Exact Sciences (US), GRAIL (US), Freenome (US), Biocept (US), Sysmex Corporation (JP), Roche Diagnostics (CH), Qiagen (DE), Thermo Fisher Scientific (US)
Segments Covered	Application, Sample Type, Technology, End User
Key Market Opportunities	Advancements in non-invasive diagnostic technologies enhance growth potential in the Liquid Biopsy Market.
Key Market Dynamics	Technological advancements and regulatory changes drive innovation and competition in the liquid biopsy market.
Countries Covered	North America, Europe, APAC, South America, MEA